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Coronary artery disease (CAD) as well as depression are both highly prevalent
diseases. Both cause a significant decrease in quality of life for the patient and impose
a significant economic burden on society. There are several factors that seem to link
depression with the development of CAD and with a worse outcome in patients with
established CAD: worse adherence to prescribed medication and life style modifica-
tions in depressive patients, as well as higher rates in abnormal platelet function,
endothelial dysfunction and lowered heart rate variability. The evidence is growing
that depression per se is an independent risk factor for cardiac events in a patient
population without known CAD and also in patients with established diagnosis of CAD,
particularly after myocardial infarction. Treatment of depression has been shown to
improve patients' quality of life. However, it did not improve cardiovascular prognosis
in depressed patients even though there is open discussion about the trend to better
outcome in treated patients. Large scale clinical trials are needed to answer this
question. Selective serotonin reuptake inhibitors seem to be preferable to tricyclic
antidepressants for treatment of depressive patients with comorbid CAD because
of their good tolerability and absence of significant cardiovascular side effects.
Hypericum perforatum (St. John's wort), an increasingly used herbal antidepressant
drug should be used with caution due to severe and possibly dangerous interaction
with cardioactive drugs.








Recently new risk factors for coronary artery disease
(CAD) have been identified, among them emotional
distress and depression.1–5 Taking into account that life-
time prevalence of depression is as high as 17%,6 it is not
surprising that CAD and depression are often comorbid
conditions. Both of them cause a significant decrease in
quality of life for the patient and impose a signifi-
cant economic burden on society. The association of
depression and CAD has been noted already many years
ago. In the mid 19th century a paper about ‘nervous and
sympathetic palpitations of the heart’ was published.1
This publication was followed by numerous papers
describing the concept of neurologically based, or
‘neurasthenic’, cardiac disorders. In 1910, Sir William
Osler described his typical patient with angina pectoris as
‘a man whose engine is always set full speed ahead’ and
called his patients with cardiac disease ‘worriers’.7
Depression and CAD as comorbid conditions
Major depression is a highly prevalent and disabling
mental disorder that is under-diagnosed and under-
treated.6,8 High rates of disease-related disability, and
relapse or recurrence are common.9,10 Major depression
is associated with as much physical and social dysfunction
as many other common medical illnesses. Similarly, CAD
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is highly prevalent in western populations affecting men
and women with increasing age.11,12 Social dysfunction is
twice as high in patients with advanced CAD and depres-
sion as in patients with either condition alone.13–15
Depression can reliably be diagnosed by psychometric
scales and standardized clinical interviews.16–19 The
typical features are the presence of depressed mood and
markedly decreased interest in all activities, persisting
for at least 2 weeks and accompanied by at least four of
the following additional symptoms: changes in appetite,
sleep disturbances, fatigue, psychomotor retardation or
agitation, feelings of guilt or worthlessness, problems
concentrating, and suicidal thoughts.4 Various well struc-
tured questionnaires have been used and validated in the
screening process such as the Hamilton Rating Scale for
depression,16 the recent life change questionnaire,20 and
the Beck Depression Inventory.17,18 In addition, short
forms of questionnaires are available which screen for
depression and other psychiatric disorders including
mood, anxiety, alcohol, eating, and somatoform dis-
orders.19,21 It is important to utilize these simple vali-
dated questionnaires to diagnose depression in primary
care settings.
Depression, CAD and outcome
Population without known CAD
Many early studies evaluating the interaction of CAD and
depression were secondary analyses of population-based
databases and have to be interpreted with caution. None-
theless, several studies suggest an interaction between
depression and the development of CAD after adjustment
for traditional cardiovascular risk factors.22 Relative risk
for myocardial infarction in patients with depressive
symptoms versus non-depressive patients within the
same cohort ranged from 1.5 (95% CI 1.0–2.3) to 4.5 (95%
CI 1.7–12.4).23–27 An increased risk for CAD was not only
described in patients with major depression but also
in those with minor depressive symptoms and dys-
phoria.23,27 In a cohort of 2832 subjects who participated
in the National Health Examination Follow-up Study
(mean follow-up=12.4 years) and who had no history of
CAD or serious illness at baseline, 11% had depressed
affect; 10.8% reported moderate hopelessness, and 2.9%
reported severe hopelessness. Depressed affect and
hopelessness were more common among women,
blacks, and persons who were less educated, unmarried,
smokers, or physically inactive. After adjustment for
demographic and risk factors patients with depressed
affect and moderate as well as severe levels of hopeless-
ness had a relative risk to suffer fatal CAD of 1.5 (95% CI
1.0–2.3); 1.6 (95% CI=1.0–2.5) and 2.1 (95% CI=1.1–3.9),
respectively. Depressed affect and hopelessness were
also associated with an increased risk of non-fatal CAD.23
Another report in 730 patients showed that significant
depression was associated with relative risks of 1.71
(P=0.005) and 1.59 (P<0.001) for myocardial infarc-
tion and deaths from all causes, respectively after
adjustment for baseline variables.26
These findings were confirmed by several prospective
studies. The Precursors study evaluated 1190 male medi-
cal students who were followed up for 40 years.28 The
cumulative incidence of clinical depression was 12%. Men
who reported clinical depression were at significantly
greater risk for subsequent CAD and myocardial infarc-
tion than men without depression, the relative risk being
2.12 (95% CI 1.24–3.63) and 2.12 (95% CI 1.11–4.6),
respectively. Of note, the increased risk associated with
clinical depression was present even for myocardial
infarction occurring 10 years after the onset of the first
depressive episode. The authors concluded that clinical
depression appeared to be an independent risk factor
for CAD for several decades after the onset of clinical
depression.28 In The Cardiovascular Health Study evalu-
ating 5201 subjects with a follow-up of 6 years, high
levels of depressive symptoms were an independent risk
factor for mortality in community-residing older adults.
The authors hypothesized that motivational depletion
which is consistent with vital exhaustion and decreased
emotional vitality may be a key underlying mechanism
for the depression-mortality effect.29
Interaction of depression and known CAD
In patients with angiographically proven CAD and no
evidence of myocardial infarction or unstable angina the
prevalence of depression was approximately 18% in one
study.30 In patients following acute myocardial infarc-
tion, up to 25% had severe, often recurrent major depres-
sion, while 27–65% manifested symptoms diagnostic of
either major or minor depression.1,25,26,31,32 The evi-
dence that depression affects prognosis in patients with
CAD, especially in patients after myocardial infarction is
growing: reported relative risks for adverse outcome
(mainly cardiac death) range from 2.5 to 5.7.33–42 In
addition to the mortality risk associated with post-
myocardial infarction depression, increased health care
costs linked to both readmission and out-patient contact
among depressed patients who survived the first year
after infarction have been observed.43
Of note, not only full blown major depression
accounted for worse outcome: multivariate analysis in
222 patients with prior myocardial infarction demon-
strated that depressive symptoms, anxiety, and history
of major depression each had an impact on outcome
independent of each other.34 This finding was confirmed
by other studies in patients after myocardial infarction in
which mortality rates increased as a function of the
degree of depressive symptoms.38,44
Impact of major depression on prognosis was as
relevant as left ventricular dysfunction (Killip class) and
history of previous myocardial infarction33 and proved
to be a significant predictor of 1-year cardiac mortality
for women as well as for men independent of other
post-myocardial infarction risks.35 Recently, it has been
suggested that depression had a similar impact on prog-
nosis in patients with unstable angina as in patients post
myocardial infarction.37
A higher prevalence of ventricular tachycardia during
24-h Holter monitoring among patients with CAD and
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depression than among CAD patients without depression
has been noted which may contribute to the explanation
of the increased risk for cardiac mortality in depressed
patients with CAD.45
In patients with coronary artery bypass graft surgery,
it has been shown that depression diagnosed before
surgery was related to higher hospital re-admission
rates46 and was an independent risk factor for cardiac
events after surgery,39,47 suggesting that positive emo-
tions may promote better recovery.48
In summary, there is considerable evidence suggesting
that depression and comorbid CAD may lead to an
increased risk of death, regardless of which illness
occurred first.6 The most prominent finding is the
increased mortality in patients with depression after
myocardial infarction.
Pathophysiologic factors possibly linking
depression and CAD
Several studies indicated that depression may have
behavioural and direct pathophysiologic effects on CAD.
Depression is associated with non-adherence to risk
factor modification in many medical conditions,49–52
such as smoking cessation,53,54 poor patient com-
pliance,55,56 e.g. poor glycaemic control in diabetic
patients57 and poor adherence to prescribed medication
in general.56 In addition direct pathophysiologic effects
linking depression to CAD have been postulated.
Abnormal platelet function,58–62 including increased
platelet reactivity, increased levels of platelet factor 4
and -thromboglobulin, increased platelet reactivity to
serotonin and decreased platelet reactivity to adenosine
diphosphate59 have been discussed. In addition, and in
contrast to paroxetine administration, nortriptyline did
not reverse increased levels of platelet factor 4 and
-thromboglobulin measures of platelet activation in
patients with depression and CAD.60
It has also been hypothesized that hypercortisolemia
and elevated levels of corticotropin-releasing factor may
be as relevant as additional pathophysiologic mech-
anisms of depression linked to CAD 4 as well as Ω-3 fatty
acid deficiency and elevated homocysteine levels.64
Furthermore, endothelial dysfunction has been
reported in depressive patients. Fifteen patients who
met the criteria for ‘major depressive disorder’ and
lacked conventional risk factors for CAD were compared
to matched control subjects with respect to brachial
artery flow-mediated vasodilation.63 Results showed that
the only independent predictor of the amount of reactive
hyperaemia was presence or absence of depression indi-
cating that major depression in the absence of other
conventional risk factors is associated with abnormal
peripheral artery endothelial function.
In addition, patients with anxiety and depressive dis-
orders have been shown to have reduced heart rate
variability.65–68 This finding may have important prog-
nostic implications because low heart rate variability is
a powerful predictor of sudden cardiac death.69,70 Even
in healthy subjects, depressed mood was related to the
magnitude of decrease in parasympathetic cardiac con-
trol during stressors.71 In patients after a recent myo-
cardial infarction with evidence of depression, four
indices of heart rate variability were significantly
reduced compared to patients without depression66 indi-
cating that greater autonomic dysfunction as reflected
by decreased heart rate variability might be a plausible
mechanism linking depression to increased cardiac mor-
tality in post-myocardial infarction patients.66 Finally, a
direct association between the severity of depressive
symptoms and the modulation of cardiovagal activity was
found.65
Thus, abnormal platelet function, endothelial dys-
function, and reduced heart rate variability have been
identified as possible links between depression and CAD,
however, more research in large scale clinical trials is
needed to confirm these interrelationships and to assess
their changes after antidepressant treatment.
Treatment of depression in patients with
CAD
In patients with CAD, several small clinical trials suggest
that cognitive-behavioural therapy successfully reduced
anxiety and depression, and thus facilitated the modifi-
cation of cardiac risk factors.72–74 Data of the Enhancing
Recovery in Coronary Heart Disease (ENRICHD) trial have
been published recently.75,76 This randomized controlled
clinical trial evaluated 2481 patients with evidence of
depression after myocardial infarction who either under-
went treatment for depression (cognitive behavioural
therapy) or usual care. Despite the treatment group's
improvements in depression and social support, there
was no significant difference in event-free survival
(mortality and recurrent infarction) after an average
follow-up of 29 months, between usual care (75.9%) and
psychosocial intervention (75.8%).
However, several studies suggest that depressive
patients with CAD benefit from cardiac rehabilitation
programmes by improving coping skills and self image,
reducing biological risk factors such as social isolation
and smoking, by providing emotional support, and
improving quality of life scores,1,77–79 regardless of
patient age and gender.80,81 Unfortunately, drop-out
rates from rehabilitation programmes are higher in
depressive patients than in non-depressive patients.82
Therefore, depressive patients with CAD should be
encouraged to participate in cardiac rehabilitation
programmes!
Medical therapy of depression
For many years, pharmacologic treatment for patients
with depression and stable CAD was based on tricyclic
antidepressive agents (TCA), such as amitriptyline,
imipramine, nortriptyline, desipramine, and doxepin.
TCA's have several adverse effects that complicate their
use in patients with cardiac disease.1 Tricyclic anti-
depressive agents cause orthostatic hypotension, which
may result in haemodynamic instability, especially in
patients with conduction system disease and congestive
heart failure.1 Furthermore, TCA's have anticholinergic
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effects and a high potential for drug interaction. TCA's
also have significant anti-arrhythmic activity and can be
classified as type IA anti-arrhythmic agents,83–85 but also
show arrhythmogenic potential.86,87
In contrast, selective serotonine reuptake inhibitors
(SSRI) have only minimal cardiac side effects: the only
effect of citalopram on ECG findings was a small reduc-
tion in heart rate (less or equal to 8 beats per minute).
There were no significant effects on PQ, QRS, or QTc
intervals, indicating that citalopram has no effect on
cardiac conduction and repolarization during short- or
long-term treatment.88
In a study (n=81) comparing paroxetine (aSSRI) and
nortriptyline (a TCA) both treatments were similarly
effective in reducing depressive symptoms, but
paroxetine was better tolerated than nortriptyline and
less likely to produce cardiovascular side effects.89 In
patients with recent myocardial infarction or unstable
angina and without other life-threatening medical
conditions sertraline has been shown to be a safe and
effective treatment for recurrent depression.90
Another study with paroxetine demonstrated that
reduced panic attacks were paralleled by increased
parasympathetic activity but preserved baroreflex
response. The authors concluded that potential benefits
of selective serotonin reuptake inhibitors in decreasing
cardiac mortality might be achieved by the increase of
heart rate variability.91 In depressed survivors of acute
myocardial infarction sertraline facilitated the rate of
recovery of heart rate variability, a recognized predictor
of clinical outcome.92
To assess the risk of myocardial infarction, 2247
patients who received at least one prescription for an
antidepressant were compared with 52750 subjects who
did not. Patients were compared with respect to anti-
depressant treatments they received: TCA's, SSRI's, and
others. Over a follow-up of 4.5 years, antidepressant
users had a more than twofold risk to suffer a myocardial
infarction (relative risk 2.2 (95% CI 1.3 to 3.7)) when
compared with nonusers. Patients using TCA's and SSRI's
had relative risks of 2.2 (95% CI 1.2 to 3.8) and 0.8 (95% CI
0.2 to 3.5), respectively, suggesting an association
between use of TCA's and increased risk to suffer myo-
cardial infarction. In SSRI's, there was no such corre-
lation.93 However, in another study, SSRI exposure did
not substantially decrease the risk of developing first-
time acute myocardial infarction in patients free of other
factors predisposing to CAD.94
Two large prospective trials are currently running
and should provide more insight into the interaction of
depression, CAD, treatment and prognosis.
The Myocardial Infarction and Depression-Intervention
Trial (MIND-IT) will show in 2140 patients admitted for
myocardial infarction, whether antidepressant treatment
of post-myocardial infarction depression, preferably with
mirtazapine, can improve cardiac prognosis.95 In this
regard, the Sertraline Antidepressant Heart Attack Ran-
domized Trial (SADHART Study) has not only provided
safety data but also shown a trend to a better outcome in
post-myocardial infarction patients who were randomized
to treatment with sertraline compared with placebo.90
In summary, since quality of life in CAD patients with
depression is decreased, screening for psychosocial risk
factors and antidepressant therapy may be indicated,
although to date there is only limited data from random-
ized trials whether this treatment effectively reduces
morbidity and mortality. Even if survival is not improved
by antidepressive therapy, more clinical trials are
needed to define the optimal management of patients
with CAD and depression.96,97
Herbal medication
Hypericum perforatum (St. John's wort) has become a
popular alternative treatment for depression and several
randomized clinical trials have been published; however
with conflicting results.98–102 It is noteworthy that
several drug interactions of cardioactive drugs with
St. John's wort were recently published.103,104 These
interactions are probably due to the induction of cyto-
chrome P450 isoenzymes CYP3A4, CYP2C9, CYP1A2 and
the transport protein P-glycoprotein by constituent(s) in
St. John's wort. The degree of induction is unpredictable
due to factors such as the variable quality and quantity
of constituent(s) in St. John's wort preparations. In
addition, possible pharmacodynamic interactions with
SSRI's and serotonin (5-HT(1d)) receptor-agonists such as
triptans used to treat migraine were identified. These
interactions are associated with an increased risk of
adverse reactions.105 St John's wort also can endanger
the success of organ transplantations.106,107 In summary,
the growing use of herbal remedies has far exceeded the
available information on their benefits, adverse effects
and drug interactions.108,109
Conclusions and implications
Coronary artery disease as well as depression are both
highly prevalent diseases. Both of them cause a signifi-
cant decrease in quality of life for the patient and impose
a significant economic burden on society. The evidence is
growing that depression per se is an independent risk
factor to suffer a cardiac event. This has been shown in
patients with as well as without known CAD. There are
several behavioural and pathophysiologic factors that
seem to link depression with development of CAD and
with a worse outcome in patients with established
diagnosis of CAD. Treatment of depression has been
shown to improve quality of life of patients. There are
also preliminary results suggesting a trend to better
cardiovascular prognosis with antidepressive treatment
in CAD patients. One may hypothesize that patients
treated for their depression might better adhere to
risk factor modifications, prescribed medications and
rehabilitation programmes. Patients with known CAD and
evidence of depression should therefore be evaluated for
antidepressive therapy such as cognitive behavioural
therapy, complex cardiac rehabilitation programmes,
and pharmacologic treatment. Regarding pharmacologic
treatment, SSRI's may be preferred for their good
tolerability and absence of significant cardiovascular
side effects. Furthermore, one should be aware of the
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increasing use of herbal medications such as Saint John's
wort which may cause severe and possibly dangerous drug
interactions with cardioactive drugs.
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